• Users Online: 75
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Contacts Login 

 Table of Contents  
Year : 2017  |  Volume : 5  |  Issue : 2  |  Page : 35-37

Ebola virus disease: What should a dentist know? a brief review

1 Department of Periodontics, Faculty of Dentistry, Sebha University, Sebha, Libya
2 Department of Oral and Maxillofacial Prosthodontics, Faculty of Dentistry, Jazan University, Jazan, KSA
3 Department of Oral Pathology and Microbiology, Faculty of Dentistry, Sebha University, Sebha, Libya
4 Department of Periodontics, Faculty of Dentistry, Arab Medical University, Benghazi, Libya
5 Department of Oral Biology and Orthodontics, Faculty of Dentistry, Sebha University, Sebha, Libya
6 Department of Public Health Sciences, Miami University, Ohio, USA

Date of Web Publication10-Jul-2017

Correspondence Address:
Syed Wali Peeran
Department of Periodontics, Faculty of Dentistry, Sebha University, Sebha
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/dmr.dmr_9_17

Rights and Permissions

Ebola virus disease (EVD) is a severe, fatal, zoonotic, hemorrhagic disease. The current outbreak is the largest in history and has spread across continents. Consequently, it has made the WHO to declare it as a public health emergency of international concern. To the best of our knowledge, it is the first comprehensive review of EVD and its implications for the dental fraternity.

Keywords: Dentist, Ebola, Ebola virus disease, epidemics, hemorrhagic disease, infection control

How to cite this article:
Peeran SW, Peeran SA, Ramalingam K, Al Mugrabi MH, Abdalla KA, Ahmed F. Ebola virus disease: What should a dentist know? a brief review. Dent Med Res 2017;5:35-7

How to cite this URL:
Peeran SW, Peeran SA, Ramalingam K, Al Mugrabi MH, Abdalla KA, Ahmed F. Ebola virus disease: What should a dentist know? a brief review. Dent Med Res [serial online] 2017 [cited 2022 Nov 27];5:35-7. Available from: https://www.dmrjournal.org/text.asp?2017/5/2/35/210123

  Introduction Top

Ebola virus disease (EVD) is a hemorrhagic fever. It is a viral disease caused by Ebola virus. It is a zoonotic virus that belongs to family Filoviridae. Its origin though unclear could be traced to fruit bats (Pteropodidae family) and they could be its reservoir. EVD is insidious in onset with flu-like symptoms and often fatal in human and in nonhuman primates (monkeys, gorillas, and chimpanzees).[1]

Since it was first recorded in the 1970s in Sub-Saharan Africa, there have been regular outbreaks of the epidemic. The current outbreak in West Africa has shown a reported total of 17,145 confirmed, probable, and suspected cases of EVD in five affected countries (Guinea, Liberia, Mali, Sierra Leone, and the United States of America) and three previously affected countries (Nigeria, Senegal, and Spain) up to the end of 30 November. There have been 6070 reported deaths.[2]

These numbers speak that though the disease is fatal, it is far behind the silent killers such as diabetes and tuberculosis. However, the increase in connectivity and the transformation of the world into a global village has led to an alarm about the possible spread of current EVD outbreak.

  Transmission Top

Ebola virus is virulent and is highly transmittable.[3] It was introduced to humans by close contact with animals.[4],[5] In humans, the virus primarily spreads through direct contact with the infected person's body fluids (stool, urine, saliva, semen, breast milk, and semen). In a convalescent male, the virus can persist in semen for at least 70 days.[6] Contaminated objects such as needles, syringes, and contaminated materials can also transmit it indirectly.[7] It is not known to have confirmed air-borne transmission in humans.[6] The corpse of infected person and carcass of dead infected animals can also be a source of infection.

  Pathogenesis Top

EVD appears to incapacitate the immune system. It evades the host immune response and replicates in various cell types such as the hepatocytes, Kupffer cells, macrophages, and endothelial cells. This results in early viremia. There is a clear upsurge in the release of pro-inflammatory cytokines from the infected cells. The resultant immune system malfunction subsequently initiates the hemorrhage in vascular system, hypotension, and drop in blood pressure. This sets the stage for shock, multiorgan failure, and a typical death within 10 days after the appearance of symptoms. The manner, in which it shuts the major mechanisms in the host, facilitates its uncontrolled replication.[3],[8]

  Clinical Features Top

EVD has an incubation period of 2 to 21 days with shorter incubation periods in cases of exposure to contaminated material like needlestick injury.[9] The first symptoms are high-grade fever, malaise, fatigue, body aches, and sore throat.

They are followed by epigastric pain, nausea, vomiting, watery diarrhea leading to intravascular volume depletion, asthenia, headache, conjunctival injection, chest pain, abdominal pain, arthralgias, myalgias, hiccups, delirium, shock, hemorrhage including internal (gastrointestinal) and external (gingival bleeding and in stools), secondary infections, meningoencephalitis, and persistent neurocognitive abnormalities. Children and pregnant women populations are particularly vulnerable. The survival of neonates born to mothers with EVD has not been reported.[1],[3],[10],[11],[12] Malaria, typhoid fever, shigellosis, leptospirosis, yellow fever, dengue, and other viral hemorrhagic fevers are among the differential diagnoses to consider in EVD-infected patients.[13]

Laboratory findings include lymphocytopenia, thrombocytopenia, and elevated liver enzymes. Prothrombin and partial thromboplastin times are also increased.[14] Confirmation within a few days after symptoms can be obtained with enzyme-linked immunosorbent assay, polymerase chain reaction assay, and virus isolation.[15]

EVD is primarily treated symptomatically. No approved vaccine is currently available for EVD. Supportive care is critical for the patients.

  How Can We Prevent Spread of Ebola Virus Disease? Top

Extensive research evidence shows that the EVD outbreaks are potential spill over into the humans from an animal source. A recent review by Sarah et al. indicated that for the purposes of identifying potential sources of transmission from animals to humans and isolating suspected virus in an animal in outbreak situations, (1) surveillance of free-ranging nonhuman primate mortality and morbidity should be a priority, (2) any wildlife morbidity or mortality events should be investigated and may hold the most promise for locating virus or viral genome sequences, (3) surveillance of some bat species is worthwhile to isolate and detect evidence of exposure, and (4) morbidity, mortality, and serology studies of domestic animals should prioritize dogs and pigs and include testing for virus and previous exposure.[16]

Persons who come into direct contact with an infected animal, its body fluids are at risk. In affected areas, one should avoid contact with or handling of wild animals, alive or dead, or their raw or undercooked meat.[13]

EVD is highly infectious, but it can be prevented. A gist of the summary of the infection prevention and control measures by the WHO for anyone providing direct and nondirect care to patients with suspected or confirmed EVD in health-care facilities is as follows:

  • Use of hand hygiene for all patients regardless of signs and symptoms, using alcohol hand rubs, solutions or soap, and running water and single-use towels
  • Before donning gloves and wearing personal protective equipment (PPE) upon entry to the isolation area; before any clean or aseptic procedures are being performed on a patient; after any exposure risk or actual exposure with a patient's blood or bodily fluids; after touching (even potentially) contaminated surfaces, items, or equipment in the patient's surroundings; and after removal of PPE, upon leaving the isolation area
  • Before entering care areas, don PPE – this includes gloves, an impermeable long-sleeve gown, boots/closed-toe shoes with overshoes, and a mask and eye protection for splashes
  • Limit the use of needles and other sharp objects, cover abrasions, and wear PPE
  • Laboratory care: Ensure safe handling of laboratory samples, i.e., use of PPE, safe collection, and sample processes from confirmed or suspected cases
  • Safe care of the dead: Keep the handling of human remains and dead bodies to a minimum. Wear PPE. Only trained staff should undertake the recommended procedures for burial while taking into account cultural and religious concerns.[17]

Epidemiological models employed to forecast considering the end of this current EVD epidemic estimates that it should disappear within nine months and no major outbreaks (i.e., more than 10 infected cases) should be reported except in Liberia, Guinea, Sierra Leone, Nigeria, Mali, and Gambia.[18]

  Ebola Virus Disease and the Dentist Top

EVD presents initially with flu-like symptoms, with later demonstrations of its classical hemorrhagic fever symptoms. The initial oral findings may be sore throat and gingival bleeding in its later stages. Hence, the possibility of first diagnosing an EVD patient in a dental setting is uncommon. However, dental clinician and the staff must undertake proper infection control measures to avoid the risk of EVD transmission.

In the phase of postclinical recovery, the patient is said to be no longer contagious. A recovered patient can transmit the virus through semen for up to 40 days and through breast milk for 15 days which is irrelevant to dental care. A study noted that the enzymes in saliva and certain conditions in the mouth appeared to inhibit the virus from surviving for long periods. The virus was found to stay in saliva during the “acute phase of infection,” no longer than 8 days.

  Conclusion Top

The current EVD outbreak is the largest known outbreak. On August 8, the WHO director-general declared this outbreak a Public Health Emergency of International Concern. The current understanding reveals that this EVD outbreak will end soon. Nevertheless, the question that lingers is, are we prepared for the next outbreak?

Increasing the awareness of risk factors among the general population will keep us prepared for EVD outbreaks. Proper knowledge and understanding about the EVD, its pathogenesis, and prevention is vital for health-care workers to prevent such events in the future.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Schoenhagen P, Weiner M. Ebola and art. Cardiovasc Diagn Ther 2014;4:339-40.  Back to cited text no. 1
Ebola Response Road Map Situation Report. World Health Organization; 2014. p. 1-14. Available from: http://www.apps.who.int/iris/bitstream/10665/144806/1/roadmapsitrep_3Dec2014_eng.pdf?ua=1. [Last accessed on 2015 Jan 12].  Back to cited text no. 2
Ansari AA. Clinical features and pathobiology of Ebolavirus infection. J Autoimmun 2014;55:1-9.  Back to cited text no. 3
Weingartl HM, Embury-Hyatt C, Nfon C, Leung A, Smith G, Kobinger G. Transmission of Ebola virus from pigs to non-human primates. Sci Rep 2012;2:811.  Back to cited text no. 4
Reed DS, Lackemeyer MG, Garza NL, Sullivan LJ, Nichols DK. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: Differences in disease course and clinical pathology. Microbes Infect 2011;13:930-6.  Back to cited text no. 5
What We Know about Transmission of the Ebola Virus among Humans. Ebola Situation Assessment. World Health Organization; 2014. Available from: http://www.who.int/mediacentre/news/ebola/06-october-2014/en/. [Last accessed on 2015 Jan 12].  Back to cited text no. 6
Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Ströher U, Grolla A, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007;3:e2.  Back to cited text no. 7
Wong G, Kobinger GP, Qiu X. Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol 2014;10:781-90.  Back to cited text no. 8
Factsheet for Health Professionals. European Centre for Disease Prevention and Control. Available from: http://www.ecdc.europa.eu/en/healthtopics/ebola_marburg_fevers/factsheet-for-health-professionals/Pages/factsheet_health_professionals.aspx?preview=yes&pdf=yes. [Last updated on 2014 Sep 11].  Back to cited text no. 9
Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. Ebola virus disease in West Africa – Clinical manifestations and management. N Engl J Med 2014;371:2054-7.  Back to cited text no. 10
Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978;56:271-93.  Back to cited text no. 11
Mupapa K, Mukundu W, Bwaka MA, Kipasa M, De Roo A, Kuvula K, et al. Ebola hemorrhagic fever and pregnancy. J Infect Dis 1999;179 Suppl 1:S11-2.  Back to cited text no. 12
World Health Organization. September 2014 Travel and Transport Risk Assessment: Interim Guidance for Public Health Authorities and the Transport Sector. Available from: http://www.who.int/csr/resources/publications/ebola/travel-guidance/en/. [Last assessed on 2016 Dec].  Back to cited text no. 13
Feldmann H, Sanchez A, Geisbert TW. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley P, editors. Fields virology. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2013.  Back to cited text no. 14
Saeidi M, Moghaddam HT, Kiani MA, Noras M, Rahban M, Hoseini BL. A short overview of Ebola outbreak. Int J Pediatr 2014;2:287-294  Back to cited text no. 15
Olson SH, Reed P, Cameron KN, et al. Dead or alive: Animal sampling during Ebola hemorrhagic fever outbreaks in humans. Emerging Health Threats Journal. 2012;5:10.3402/ehtj.v5i0.9134. doi:10.3402/ehtj.v5i0.9134.  Back to cited text no. 16
World Health Organization. Infection Prevention and Control (IPC) Guidance Summary. Ebola Guidance Package. Available form: http://apps.who.int/iris/bitstream/10665/131828/1/WHO_EVD_Guidance_IPC_14.1_eng.pdf: World Health Organization; 2014.  Back to cited text no. 17
Ivorra B, Ngom D, Ramos AM. Be-CoDiS: An Epidemiological Model to Predict the Risk of Human Diseases Spread between Countries. Validation and Application to the 2014 Ebola Virus Disease Epidemic. Available from: http://www.arxiv.org/abs/1410.6153. [Last assessed on 2016 Dec].  Back to cited text no. 18


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article
Clinical Features
How Can We Preve...
Ebola Virus Dise...

 Article Access Statistics
    PDF Downloaded1248    
    Comments [Add]    

Recommend this journal